Navigation Links
Dynavax to Present at Bear Stearns 20th Annual Healthcare Conference
Date:9/6/2007

BERKELEY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Dr. Dino Dina, President and Chief Executive Officer, will present an overview of the company at the Bear Stearns 20th Annual Healthcare Conference in New York, New York on Monday, September 10th at 9:00 a.m. Eastern Daylight Savings Time (6:00 a.m. PDST). The presentation will be webcast.

To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.

ABOUT DYNAVAX

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA, a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. Our preclinical work on a vaccine for influenza is partially funded by the NIH. Our colorectal cancer trial and our preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.


'/>"/>
SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in order to improve teacher quality, the field must first improve teacher preparation ... popular reform to the next” and that decades of input- and outcome-based research ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield ... Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, and ... estate valuation industry for more than 40 years. , “Ruel is a great ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... , Va. and PHOENIX , March 28, ... Avella Specialty Pharmacy released a new white ... allergies and the use of latex in healthcare. Specifically, there ... in healthcare. In fact, the FDA has urged manufacturers to ... latex" claim from labels, because of the challenge to ensure ...
Breaking Medicine Technology: